Skip to main content
Terug
DNLI logo

Denali Therapeutics Inc.

Datakwaliteit: 100%
DNLI
NASDAQ Healthcare Biotechnology
€ 21,09
▲ € 0,92 (4,56%)
Marktkapitalisatie: 3,34B
Dagbereik
€ 20,74 € 21,67
52-Weeksbereik
€ 10,57 € 23,77
Volume
1.552.403
50D / 200D Gem.
€ 20,15 / € 16,67
Vorige Slotkoers
€ 20,17

Koershistorie

Financiële Trends

Sectorvergelijking

vs Healthcare sector mediaan (626 peers)

Metriek Aandeel Sector Mediaan
P/E -6,5 0,4
P/B 3,3 2,9
ROE % -45,7 3,8
Net Margin % 3,9
Rev Growth 5Y % 10,0
D/E 0,0 0,2

Belangrijkste Punten

Debt/Equity of 0,04 — conservative balance sheet
Negative free cash flow of -422,10M

Groei

Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Kwaliteit

Return on Equity
-45,69%
ROIC-39,44%
Net MarginN/A
Op. MarginN/A

Veiligheid

Debt / Equity
0,04
Current Ratio9,16
Interest Coverage0,00

Waardering

P/E Ratio
-6,53
P/B Ratio3,30
EV/EBITDAN/A
Dividend Yield0,00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) N/A Revenue Growth (3Y) N/A
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 0,0 Net Income (TTM) -512,54M
ROE -45,69% ROA -44,77%
Gross Margin N/A Operating Margin N/A
Net Margin N/A Free Cash Flow (TTM) -422,10M
ROIC -39,44% FCF Growth (3Y) N/A
Safety
Debt / Equity 0,04 Current Ratio 9,16
Interest Coverage 0,00 Dividend Yield 0,00%
Valuation
P/E Ratio -6,53 P/B Ratio 3,30
P/S Ratio N/A PEG Ratio -0,36
EV/EBITDA N/A Dividend Yield 0,00%
Market Cap 3,34B Enterprise Value 3,18B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 0,0 0,0 330,53M 108,46M 48,66M
Net Income -512,54M -422,77M -145,22M -325,99M -290,58M
EPS (Diluted) -2,97 -2,57 -1,06 -2,60 -2,39
Gross Profit -11,18M 0,0 330,53M 108,46M 48,66M
Operating Income -555,34M -487,34M -196,70M -340,74M -295,75M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 1,14B 1,37B 1,15B 1,46B 1,40B
Total Liabilities 131,09M 144,50M 122,96M 417,81M 441,87M
Shareholders' Equity 1,01B 1,23B 1,03B 1,04B 962,29M
Total Debt 42,29M 48,71M 52,24M 60,35M 64,01M
Cash & Equivalents 205,33M 174,96M 127,11M 218,04M 293,48M
Current Assets 900,66M 864,44M 1,06B 1,37B 897,23M
Current Liabilities 98,35M 102,21M 77,98M 363,92M 378,25M